We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-3.06%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$77.7B
AUM Growth
-$3.9B
Cap. Flow
+$505M
Cap. Flow %
0.65%
Top 10 Hldgs %
24.09%
Holding
3,066
New
55
Increased
1,481
Reduced
1,461
Closed
51

Top Buys

Rank Stock Value
1
AMD icon
Advanced Micro Devices
AMD
+$83.5M
2
SPGI icon
S&P Global
SPGI
+$73.5M
3
TSLA icon
Tesla
TSLA
+$55.8M
4
MSFT icon
Microsoft
MSFT
+$45.9M
5
AMZN icon
Amazon
AMZN
+$27.9M

Sector Composition

Rank Sector Weight
1 Technology 24.74%
2 Financials 13.53%
3 Healthcare 13.01%
4 Consumer Discretionary 11.66%
5 Industrials 8.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AROW icon
2326
Arrow Financial
AROW
$644M
$614K ﹤0.01%
20,093
-1,721
-8% -$56.4K
PTLO icon
2327
Portillo's
PTLO
$323M
$614K ﹤0.01%
24,990
+2,941
+13% +$77.9K
FPI
2328
Farmland Partners
FPI
$418M
$613K ﹤0.01%
44,558
-3,089
-6% -$37.4K
RBCAA icon
2329
Republic Bancorp
RBCAA
$1.91B
$613K ﹤0.01%
13,635
-1,260
-8% -$60.3K
REAL icon
2330
The RealReal
REAL
$1.49B
$613K ﹤0.01%
84,401
+896
+1% +$7.93K
THR
2331
DELISTED
Thermon Group Holdings
THR
$612K ﹤0.01%
37,807
-4,643
-11% -$80.7K
OUST icon
2332
Ouster
OUST
$2.87B
$610K ﹤0.01%
13,549
+631
+5% +$23.3K
NSSC icon
2333
Napco Security Technologies
NSSC
$1.45B
$609K ﹤0.01%
29,688
+800
+3% +$16.6K
NGM
2334
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$607K ﹤0.01%
39,806
-2,720
-6% -$42.4K
QUOT
2335
DELISTED
Quotient Technology Inc
QUOT
$607K ﹤0.01%
95,219
-2
-0% -$13
ADV icon
2336
Advantage Solutions
ADV
$362M
$605K ﹤0.01%
3,796
-47
-1% -$8.13K
VPG icon
2337
Vishay Precision Group
VPG
$885M
$605K ﹤0.01%
18,824
-1,517
-7% -$49.2K
TBPH icon
2338
Theravance Biopharma
TBPH
$875M
$604K ﹤0.01%
63,183
+652
+1% +$6.39K
TPC
2339
Tutor Perini Cor
TPC
$5.26B
$604K ﹤0.01%
55,967
-6,567
-11% -$73.6K
AMRX icon
2340
Amneal Pharmaceuticals
AMRX
$5.77B
$603K ﹤0.01%
144,582
-13,640
-9% -$60.4K
CLSK icon
2341
CleanSpark
CLSK
$3.01B
$600K ﹤0.01%
48,466
+6,407
+15% +$59.2K
HYFM icon
2342
Hydrofarm Holdings
HYFM
$8.86M
$600K ﹤0.01%
3,963
+294
+8% +$54.9K
EQBK icon
2343
Equity Bancshares
EQBK
$1.04B
$599K ﹤0.01%
18,548
-1,692
-8% -$55K
VSEC icon
2344
VSE Corp
VSEC
$6.16B
$599K ﹤0.01%
12,986
-1,380
-10% -$68.8K
AVIR icon
2345
Atea Pharmaceuticals
AVIR
$404M
$594K ﹤0.01%
82,237
-4,002
-5% -$27.2K
OSW icon
2346
OneSpaWorld
OSW
$2.6B
$592K ﹤0.01%
58,008
+1,319
+2% +$13.4K
MCRB icon
2347
Seres Therapeutics
MCRB
$48.6M
$588K ﹤0.01%
4,129
-8
-0.2% -$1.23K
MOFG
2348
DELISTED
MidWestOne Financial Group
MOFG
$588K ﹤0.01%
17,779
-1,934
-10% -$61.8K
VVX icon
2349
V2X
VVX
$2.64B
$587K ﹤0.01%
16,368
-2,024
-11% -$86.5K
UFPT icon
2350
UFP Technologies
UFPT
$2.47B
$585K ﹤0.01%
8,835
-683
-7% -$46.9K

Similar funds

RhumbLine Advisers's Q1 2022 Portfolio in Review

As of Q1 2022, RhumbLine Advisers held 3,066 positions worth $77.7B, down 4.8% from $81.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 3.5%. RhumbLine Advisers opened 55 new positions and exited 51, leaving the 3,066-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q1 2022 buy was Constellation Energy: 528,261 shares worth $29.7M.
  • RhumbLine Advisers added most to Advanced Micro Devices in Q1 2022, an estimated $83.5M increase.
  • RhumbLine Advisers's biggest Q1 2022 reduction was Abbott, cutting an estimated $25.5M.
  • RhumbLine Advisers fully exited Xilinx Inc in Q1 2022, selling an estimated $88.8M.
  • RhumbLine Advisers's ten largest holdings make up 24% of its $77.7B portfolio in Q1 2022.
  • RhumbLine Advisers opened 55 new positions and closed 51 in Q1 2022.
  • RhumbLine Advisers's portfolio value fell 4.8% quarter-over-quarter to $77.7B.

Based on RhumbLine Advisers's 13F filing for Q1 2022, filed 12 May 2022.